Pharmacologic treatment of calcium calculi.
Selective pharmacologic therapy of calcium nephrolithiasis is highly effective in preventing new stone formation. A remission rate of greater than 80 per cent and overall reduction in individual stone formation rate of greater than 90 per cent can be obtained in patients with calcium nephrolithiasis. In patients with mild-to-moderate severity of stone disease, virtually total control of stone disease can be achieved as evidenced by remission rates of greater than 95 per cent. The need for stone removal may be dramatically reduced by an effective prophylactic program. Selective pharmacologic therapy of calcium nephrolithiasis also encompasses the advantages of overcoming the nonrenal manifestations of conditions that cause stone formation as well as averting certain side effects that may be caused by nonselective medical therapy. Despite these advantages, selective medical therapy clearly cannot provide total control of stone disease. A satisfactory response requires continued, dedicated compliance by patients to the recommended program and a commitment of the physician to provide long-term follow-up and care.
D001581:Benzothiadiazines; D002118:Calcium / Q000652:urine*; D002482:Cellulose / Q000031:analogs & derivatives / Q000627:therapeutic use; D002951:Citrates / Q000627:therapeutic use / Q000652:urine; D019343:Citric Acid; D004232:Diuretics; D006801:Humans; D007475:Ion Exchange Resins / Q000627:therapeutic use; D007669:Kidney Calculi / Q000188:drug therapy* / Q000652:urine; D010070:Oxalates / Q000652:urine; D010710:Phosphates / Q000627:therapeutic use; D049993:Sodium Chloride Symporter Inhibitors / Q000627:therapeutic use; D014527:Uric Acid / Q000652:urine
D001581:Benzothiadiazines; D002951:Citrates; D004232:Diuretics; D007475:Ion Exchange Resins; D010070:Oxalates; D010710:Phosphates; D049993:Sodium Chloride Symporter Inhibitors; D014527:Uric Acid; D019343:Citric Acid; D002482:Cellulose; C008881:phosphocellulose; D002118:Calcium